Abstract
The aim of this study was to determine the seropositivity of Hepatitis B virus (HBV) and Hepatitis C virus (HCV) dual infection among blood donors in Nyala Teaching Hospital, which is the biggest (400 beds) hospital in great Dar Fur of Western Sudan. 400 blood donors were tested serologically for the detection of HBsAg and anti-HCV antibodies. Only one (0.25%) out of the 400 examined blood donors was detected reactive for both HBsAg and anti-HCV antibodies. The study concluded that the seropositivity of HBV and HCV dual infection among population studied is uncommon.
Highlights
Dual infection with Hepatitis B virus (HBV) and hepatitis C virus (HCV) leads to more aggressive liver disease [1]
The study concluded that the seropositivity of HBV and HCV dual infection among population studied is uncommon
Serum samples initially tested for HBsAg and anti-HCV antibodies with Immunochromatographic Test (ICT) from Advanced Quality, screened with a 3rd generation Enzyme Linked Immunosorbent Assay (ELISA), EquiHBsAg and EIAgen anti-HCV antibodies from Equibar and Adalits respectively
Summary
Dual infection with HBV and HCV leads to more aggressive liver disease [1]. In addition to chronic liver disease, coinfection of HBV and HCV is frequently found in injection drug users (IDU, 42.5%) [2], patients on hemodialysis (3.7%) [3], patients undergoing organ transplantation (8%) [4], HIV-positive individuals (66%) [5], and betathalassemia patients (10%) [6], which means that those are the high risk population for infection of HBV and HCV concurrently. As HBV and HCV have the same transmission routes, dual infection may occur [7]. No published data of the seropostivity of HBV and HCV dual infection in great Dar Fur, and may be in the large Sudan.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
